UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Nevada 27-3425913 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common stock, $0.001 par value CTXR Nasdaq Capital Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2024 OR ☐ TRANSITION REPORT PURSUAN ...

LYMPHIR™ for the treatment of cutaneous T-cell lymphoma approved by the FDA Citius Pharmaceuticals, Inc. holds approximately 90% of publicly traded Citius Oncology, Inc. Shares of Citius Oncology, Inc. anticipated to begin trading on Nasdaq under the ticker "CTOR" on August 13, 2024 CRANFORD, N.J., Aug. 12, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in- ...

Management call scheduled for Tuesday, August 13, 2024, at 8:30 AM ET CRANFORD, N.J., Aug. 12, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), today announced that it will host an investor call on Tuesday, August 13, 2024 at 8:30 am ET to discuss recent and upcoming developments. Citius Chairman and CEO, Leonard Mazur, will be joined by members of the management team. A question and answer period will follow management's discussion. Conference Call Detail ...

TenX Keane shareholders voted to approve the previously announced merger with Citius Oncology at an extraordinary general meeting held on August 2, 2024 Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. Transaction expected to support commercialization of LYMPHIR, if approved, and exploration of additional oncology assets New York, NY, Aug. 05, 2024 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (NASDAQ:TENKU, TENK, TENKR))) (the "TenX"), a publicly traded special purpose acquisition comp ...

Citius Pharmaceuticals to receive 65.6 million shares of TenX Keane, which will be renamed Citius Oncology, Inc. Citius Pharmaceuticals to retain approximately 90% majority control post transaction Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. Transaction expected to support commercialization of LYMPHIR, if approved, and exploration of additional oncology assets CRANFORD, N.J., Aug. 5, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CT ...

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 18, 2024) - Investorideas.com, a goto investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The Company's diversified pipeline includes two late-stage product candidates. Read the full article on Investorideas. ...

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 17, 2024) - Investorideas.com, a goto investing platform releases the first of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The Company's diversified pipeline includes two late-stage product candidates. Read the full article on Investorideas.c ...

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 11, 2024) - Investorideas.com, a goto investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The Company's diversified pipeline includes two late-stage product candid ...

Core Insights - Citius Pharmaceuticals, Inc. has announced expected milestones for the second half of 2024 and highlighted key achievements year-to-date [1][19][27] Group 1: Product Developments - Mino-Lok has shown positive topline data from its Phase 3 study for treating catheter-related bloodstream infections, meeting both primary and secondary endpoints with statistical significance [2][36] - LYMPHIR, a recombinant fusion protein, is currently under FDA review with a Biologics License Application accepted, and a decision is expected on August 13, 2024 [4][20][35] - Halo-Lido, a topical treatment for hemorrhoids, has shown meaningful symptom reduction in trials and is preparing for further FDA engagement [12][30][21] Group 2: Market Potential and Strategy - Mino-Lok is positioned to be the first FDA-approved treatment for salvaging infected central venous catheters, potentially reducing serious adverse events and healthcare costs [36][27] - The company is preparing for the commercialization of LYMPHIR if approved, which could provide significant value creation opportunities [11][27] - Citius has advanced its late-stage product candidates significantly in the first half of 2024, with several key milestones anticipated [19][27] Group 3: Industry Trends - The global biopharmaceutical market is projected to grow from USD 436.7 billion in 2023 to USD 1 trillion by 2033, reflecting a compound annual growth rate of 15.4% [18] - The integration of AI and machine learning is transforming the biotech sector, with companies like Recursion leveraging these technologies for drug discovery [10][15][34]

CRANFORD, N.J., July 10, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced expected milestones in the second half of calendar 2024 and recapped key achievements year-to-date Citius significantly advanced its two late-stage product candidates in the first six months of 2024, and expects several key milestones in the nea ...